US FDA publishes FY 2013 user fees for biosimilars and branded drugs, biologics
This article was originally published in SRA
The US Food and Drug Administration will charge $1,958,800 to review a marketing application for a biosimilar product that requires clinical data in fiscal year 2013 – the same as the amount it will charge to review a similar type of application for an innovative medicine1,2.
You may also be interested in...
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.